Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Q3 2022 Earnings Call Transcript
06:00pm, Tuesday, 25'th Oct 2022 The Motley Fool
NVS earnings call for the period ending September 30, 2022.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
04:14pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
Novartis AG (NVS) Q3 2022 Earnings Call Transcript
01:42pm, Tuesday, 25'th Oct 2022
Novartis AG (NYSE:NVS ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
01:32pm, Tuesday, 25'th Oct 2022
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
Novartis: Healthy Results
11:38am, Tuesday, 25'th Oct 2022
Novartis reported revenues and earnings that were down year over year. Currency rate movements were responsible for that, however, Novartis' underlying performance was pretty solid.
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
10:50am, Tuesday, 25'th Oct 2022 The Motley Fool
Biosimilars are bringing down prescription drug costs without sacrificing quality.
US Stock Futures Down; Big Tech Earnings In Focus
10:02am, Tuesday, 25'th Oct 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the
Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff
09:03am, Tuesday, 25'th Oct 2022
Novartis stock was mostly unmoved Tuesday after the company's earnings beat expectations, but third-quarter sales came up short. The post Novartis Offers Mixed Earnings Report As It Approaches A Key S
Novartis earnings and sales fall short of expectations, but backs 2022 view
01:34am, Tuesday, 25'th Oct 2022
Corrections & Amplifications
Novartis hemoglobinuria trial meets two primary endpoints
06:27am, Monday, 24'th Oct 2022 MarketWatch
The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia.
Novartis hemoglobinuria trial meets two primary endpoints
02:27am, Monday, 24'th Oct 2022
Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.
What's in Store for Novartis (NVS) This Earnings Season?
04:26pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
What's in Store for Novartis (NVS) This Earnings Season?
01:33pm, Thursday, 20'th Oct 2022
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
3 Reasons To Love Johnson & Johnson, But Buy These 2 Better Dividend Aristocrat Bargains
11:15am, Thursday, 20'th Oct 2022 Seeking Alpha
Johnson & Johnson has a recession-resistant business model, but these two stocks are higher yielding A-rated defensive aristocrats with superior growth prospects and much better valuations.
Parnassus Endeavor Fund Enters 3 Positions, Exits 3 in 3rd Quarter
05:49pm, Monday, 17'th Oct 2022
The Parnassus Endeavor Fund (Trades, Portfolio) disclosed in regulatory filings that its top trades during the third quarter included new holdings in Ball Corp. ( BALL , Financial), Oracle Corp. ( ORC
